Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Calcinotto, Arianna ^a,j   Brevi, Arianna ^a,b   Chesi, Marta ^c   Ferrarese, Roberto ^a   Garcia Perez, Laura ^d   Grioni, Matteo ^a   Kumar, Shaji ^e   Garbitt, Victoria M ^c   Sharik, Meaghen E ^c   Henderson, Kimberly J ^e   Tonon, Giovanni ^a   Tomura, Michio ^f   Miwa, Yoshihiro ^g   Esplugues, Enric ^h   Flavell, Richard A ^h   Huber, Samuel ^d   Canducci, Filippo ^a,i   Rajkumar, Vincent S ^e   Bergsagel, P Leif ^c   Bellone, Matteo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MAYO CLINIC   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e MAYO CLINIC ROCHESTER   (United States)

^f OSAKA OHTANI UNIVERSITY   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h YALE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF INSUBRIA   (Italy)

^j INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; STAT3 PROTEIN;

CANCER; CELL; DIFFERENTIATION; DIGESTIVE SYSTEM; DISEASE PREVALENCE; IMMUNITY; MICROORGANISM; TUMOR;

ANIMAL EXPERIMENT; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDETES; CANCER GROWTH; CELL DIFFERENTIATION; CELL SURVIVAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EOSINOPHIL; IN VITRO STUDY; INNATE IMMUNITY; INTESTINE FLORA; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PARACRINE SIGNALING; PREVOTELLA; PREVOTELLA HEPARINOLYTICA; PROTEIN PHOSPHORYLATION; SOMATIC HYPERMUTATION; TH17 CELL; TUMOR GROWTH; ANIMAL; BONE MARROW; C57BL MOUSE; CELL MOTION; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MURINAE; MUS; PREVOTELLA HEPARINOLYTICA;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL MOVEMENT; DISEASE PROGRESSION; EOSINOPHILS; GASTROINTESTINAL MICROBIOME; HUMANS; INTERLEUKIN-17; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPLE MYELOMA; PREVOTELLA; TH17 CELLS;

EID: 85057599323     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-07305-8     Document Type: Article

References (65)

1. Garrett, W. S. Cancer and the microbiota. Science 348, 80–86 (2015).
2. Schwabe, R. F. & Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 13, 800–812 (2013).
3. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
4. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
5. Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585–600 (2014).
6. Muranski, P. & Restifo, N. P. Essentials of Th17 cell commitment and plasticity. Blood 121, 2402–2414 (2013).
7. McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621–637 (2014).
8. Tartour, E. et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59, 3698–3704 (1999).
9. Noonan, K. et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116, 3554–3563 (2010).
10. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457–1464 (2009).
11. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046–1060 (2011).
12. Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).
13. Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069–3075 (2015).
14. Chesi, M. et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13, 167–180 (2008).
15. Radl, J. & Hollander, C. F. Homogeneous immunoglobulins in sera of mice during aging. J. Immunol. 112, 2271–2273 (1974).
16. Ivanov, I. I. & Honda, K. Intestinal commensal microbes as immune modulators. Cell Host Microbe 12, 496–508 (2012).
17. Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376–385 (2012).
18. Chesi, M. et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat. Med. 22, 1411–1420 (2016).
19. Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of prevotella. Cell Metab. 22, 971–982 (2015).
20. Marietta, E. V. et al. Suppression of Inflammatory Arthritis by Human Gut-Derived Prevotella histicola in Humanized Mice. Arthritis Rheumatol. 68, 2878–2888 (2016).
21. Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15, 1016–1022 (2009).
22. Grivennikov, S. I. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254–258 (2012).
23. Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 27–40 (2015).
24. de Aquino, S. G. et al. Periodontal pathogens directly promote autoimmune experimental arthritis by inducing a TLR2- and IL-1-driven Th17 response. J. Immunol. 192, 4103–4111 (2014).
25. Wagner, N. et al. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 382, 366–370 (1996).
26. Tomura, M. et al. Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice. Proc. Natl Acad. Sci. USA 105, 10871–10876 (2008).
27. Gagliani, N. et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523, 221–225 (2015).
28. Krebs, C. F. et al. Autoimmune renal disease is exacerbated by S1P-receptor-1-dependent intestinal Th17 cell migration to the kidney. Immunity 45, 1078–1092 (2016).
29. Nakae, S. et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17, 375–387 (2002).
30. Dhodapkar, K. M. et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112, 2878–2885 (2008).
31. Prabhala, R. H. et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115, 5385–5392 (2010).
32. Prabhala, R. H. et al. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia 30, 379–389 (2016).
33. Calcinotto, A. et al. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma. Oncoimmunology 4, e1008850 (2015).
34. Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34–40 (1998).
35. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003).
36. Agarwal, A. & Ghobrial, I. M. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin. Cancer Res. 19, 985–994 (2013).
37. Chu, V. T. et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 12, 151–159 (2011).
38. Zehentmeier, S. et al. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. Eur. J. Immunol. 44, 2306–2317 (2014).
39. Dahinden, C. A. et al. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J. Exp. Med. 179, 751–756 (1994).
40. Cheung, P. F., Wong, C. K. & Lam, C. W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J. Immunol. 180, 5625–5635 (2008).
41. Dyer, K. D. et al. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J. Immunol. 181, 4004–4009 (2008).
42. Rosenberg, H. F., Dyer, K. D. & Foster, P. S. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol. 13, 9–22 (2013).
43. Wong, D. et al. Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS ONE 9, e109018 (2014).
44. Enzler, T. et al. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med. 197, 1213–1219 (2003).
45. Rutkowski, M. R. & Conejo-Garcia, J. R. Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. Oncoscience 2, 239–246 (2015).
46. Rao, V. P. et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 66, 7395–7400 (2006).
47. Lakritz, J. R. et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget 6, 9387–9396 (2015).
48. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013).
49. Mangalam, A. et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 20, 1269–1277 (2017).
50. Cosorich, I. et al. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci. Adv. 3, e1700492 (2017).
51. Ley, R. E. Gut microbiota in 2015: prevotella in the gut: choose carefully. Nat. Rev. Gastroenterol. Hepatol. 13, 69–70 (2016).
52. Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
53. Potter, M. & Boyce, C. R. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 193, 1086–1087 (1962).
54. Suematsu, S. et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl Acad. Sci. USA 89, 232–235 (1992).
55. Yau, A. C. Y., Lonnblom, E., Zhong, J. & Holmdahl, R. Influence of hydrocarbon oil structure on adjuvanticity and autoimmunity. Sci. Rep. 7, 14998 (2017).
56. Di Lullo, G., Marcatti, M. & Protti, M. P. Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates. Oncoimmunology 5, e1093278 (2015).
57. Matthes, T., Manfroi, B. & Huard, B. Revisiting IL-6 antagonism in multiple myeloma. Crit. Rev. Oncol. Hematol. 105, 1–4 (2016).
58. Anderson, K. C., Jones, R. M., Morimoto, C., Leavitt, P. & Barut, B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73, 1915–1924 (1989).
59. Langley, R. G. et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N. Engl. J. Med. 371, 326–338 (2014).
60. Bel, E. H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189–1197 (2014).
61. Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014).
62. Shou, Y. et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl Acad. Sci. USA 97, 228–233 (2000).
63. Affer, M. et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 28, 1725–1735 (2014).
64. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745–757 (2011).
65. Zhan, F. et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109, 4995–5001 (2007).